selected publications

• article

  • Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.  Arthritis %26 rheumatology (Hoboken, N.J.).  67:2759-2770. 2015-01-01
  • Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.  Arthritis and Rheumatism.  62:1792-1802. 2010-01-01
  • Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.  The Lancet.  372:383-391. 2008-01-01